ICU Medical, Inc. $ICUI Shares Acquired by Blue Trust Inc.

Blue Trust Inc. boosted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 17.6% in the 2nd quarter, Holdings Channel reports. The firm owned 942 shares of the medical instruments supplier’s stock after buying an additional 141 shares during the period. Blue Trust Inc.’s holdings in ICU Medical were worth $124,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC lifted its position in ICU Medical by 27.2% in the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 153 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of ICU Medical during the 1st quarter worth $859,000. Vontobel Holding Ltd. acquired a new position in shares of ICU Medical during the 1st quarter worth $235,000. EP Wealth Advisors LLC acquired a new position in shares of ICU Medical during the 1st quarter worth $479,000. Finally, Vident Advisory LLC acquired a new position in ICU Medical in the 1st quarter valued at $270,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Performance

Shares of ICUI opened at $116.49 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26. The firm’s 50 day moving average price is $123.34 and its two-hundred day moving average price is $130.20. The firm has a market cap of $2.88 billion, a P/E ratio of -76.64 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.44 by $0.66. The firm had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The business’s revenue was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain purchased 21,929 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were purchased at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the transaction, the chief executive officer owned 130,149 shares of the company’s stock, valued at $14,686,013.16. The trade was a 20.26% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Greenberg purchased 1,200 shares of the company’s stock in a transaction on Wednesday, August 27th. The shares were purchased at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares of the company’s stock, valued at approximately $1,006,303.20. This represents a 17.75% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ICUI. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. Raymond James Financial cut their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Finally, Piper Sandler raised their price objective on shares of ICU Medical from $145.00 to $153.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $181.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.